Orexo AB (ORX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orexo AB (ORX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10149
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedure-induced pain; OX-CLI for respiratory tract diseases; and OX-MPI for inflammation. The company employs its proprietary drug delivery technologies in the development of these products. It also carries out the industrial-scale production of pharmaceutical products. Orexo works in collaboration with various pharmaceutical companies including, Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB (ORX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orexo AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orexo AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orexo AB, Medical Devices Deals, 2012 to YTD 2018 10
Orexo AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orexo AB, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orexo Enters into Commercialization Agreement with inVentiv Health for Zubsolv 12
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 13
Licensing Agreements 14
Mundipharma International Enters into Licensing Agreement with Orexo 14
Equity Offering 15
Orexo Raises USD50 Million in Private Placement of Shares 15
Debt Offering 17
Orexo Raises USD76 Million in Public Offering of Bond 17
Asset Transactions 18
Gesynta Pharma Acquires OX-MPI Program from Orexo 18
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 19
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo 20
ProStrakan Acquires Abstral From Orexo For US$85 Million 22
Acquisition 23
Orexo Divests Kibion 23
Orexo AB – Key Competitors 24
Orexo AB – Key Employees 25
Orexo AB – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Oct 25, 2018: Orexo: Interim Report Q3 2018 27
Jul 11, 2018: Orexo: Interim Report Q2 2018 29
Apr 26, 2018: Orexo – Interim Report Q1 2018 30
Jan 25, 2018: Orexo: Full Year Report Q4 2017 31
Oct 19, 2017: Orexo Interim Report Q3 2017 32
Jul 11, 2017: Orexo Interim Report Q2 2017 33
Apr 20, 2017: Orexo: Interim Report Q1 2017 40
Jan 26, 2017: Orexo: Full Year Report 2016 41
Corporate Communications 42
Oct 24, 2018: Orexo appoints Joseph DeFeo as new CFO 42
May 31, 2018: Orexo’s CFO resigns and will leave the company in November 2018 43
Government and Public Interest 44
Sep 05, 2017: Orexo, together with Malmo University, receives research grant 44
Other Significant Developments 45
Oct 01, 2018: Orexo internalizes contract Field force in the US to further strengthen the commercial organization 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Orexo AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orexo AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orexo AB, Deals By Therapy Area, 2012 to YTD 2018 9
Orexo AB, Medical Devices Deals, 2012 to YTD 2018 10
Orexo AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orexo Enters into Commercialization Agreement with inVentiv Health for Zubsolv 12
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 13
Mundipharma International Enters into Licensing Agreement with Orexo 14
Orexo Raises USD50 Million in Private Placement of Shares 15
Orexo Raises USD76 Million in Public Offering of Bond 17
Gesynta Pharma Acquires OX-MPI Program from Orexo 18
AstraZeneca Acquires Rights to OX-CLI Project from Orexo 19
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo 20
ProStrakan Acquires Abstral From Orexo For US$85 Million 22
Orexo Divests Kibion 23
Orexo AB, Key Competitors 24
Orexo AB, Key Employees 25
Orexo AB, Subsidiaries 26

List of Figures
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orexo AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orexo AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orexo AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Orexo AB (ORX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Macy’s Inc:戦略・SWOT・企業財務分析
    Macy's Inc - Strategy, SWOT and Corporate Finance Report Summary Macy's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • EyeGate Pharmaceuticals Inc (EYEG):医療機器:M&Aディール及び事業提携情報
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • North Energy ASA (NORTH):石油・ガス:M&Aディール及び事業提携情報
    Summary North Energy ASA (North Energy) is an upstream oil and gas company that provides exploration and development services in Norwegian Continental Shelf (NCS). The company’s services include oil and gas exploration and development, license mapping and drilling programs, and conducting geological …
  • Deutsche Bahn AG:企業の戦略・SWOT・財務情報
    Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Newpark Resources Inc (NR):企業の財務・戦略的SWOT分析
    Newpark Resources Inc (NR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • POP Biotechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary POP Biotechnologies Inc (POP Biotechnologies) is a biotechnology company that develops and harnesses nano-scale technologies. The company’s product portfolio comprises of NP-01, an encapsulated nanoparticle used to impart systemic drug release; and C36 product, a cobalt indulged nanoparticle …
  • Quadrise Fuels International Plc (QFI)-石油・ガス分野:企業M&A・提携分析
    Summary Quadrise Fuels International Plc (QFI), formerly Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multiphase Superfine Atomised Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation pl …
  • OPKO Health Inc (OPK):医療機器:M&Aディール及び事業提携情報
    Summary OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company’s product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vac …
  • Manz AG (M5Z)-エネルギー分野:企業M&A・提携分析
    Summary Manz AG (Manz) is a manufacturer of high-technology equipment. It produces displays, printed circuit boards and other components for electronic devices. The company provides production equipment for lithium-ion battery cells, super capacitors, battery systems, and capacitors. Manz offers ind …
  • SOCO International Plc (SIA):石油・ガス:M&Aディール及び事業提携情報
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • Toppan Forms Co Ltd:企業の戦略・SWOT・財務分析
    Toppan Forms Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Toppan Forms Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Simulations Plus Inc (SLP):企業の財務・戦略的SWOT分析
    Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • KCA Deutag Alpha Ltd:企業の戦略的SWOT分析
    KCA Deutag Alpha Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • The Macerich Co:企業のM&A・事業提携・投資動向
    The Macerich Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Macerich Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Tenaska Inc:企業の発電所・SWOT分析2018
    Tenaska Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Alteogen Inc (196170):製薬・医療:M&Aディール及び事業提携情報
    Summary Alteogen Inc (Alteogen) is a biotech company that develops proprietary antibody-drug conjugate and antibody biosimilars. The company’s pipeline products include ALT-P1, ALT-Q2, ALT-P7, ALT-Q5, ALT-L9 and ALT-L2. Its products are used for long-acting human growth hormone, long-acting factor V …
  • Aegean Airlines S.A.:企業の戦略・SWOT・財務情報
    Aegean Airlines S.A. - Strategy, SWOT and Corporate Finance Report Summary Aegean Airlines S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Knight Therapeutics Inc (GUD):企業の財務・戦略的SWOT分析
    Summary Knight Therapeutics Inc (Knight Therapeutics) focuses on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. The company offers tablets to treat metabolic, renal diseases and cancer; and injections against chronic pain and hormone …
  • Ferguson Enterprises Inc:企業の戦略的SWOT分析
    Ferguson Enterprises Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Globin Solutions Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Globin Solutions Inc (Globin) is a pre-clinical stage biotechnology company with focus on the research and development of antidotal medicines for human poisoning. Its lead compound, Ngb H64Q, an antidote, a mutant version of the protein neuroglobin, has been found to scavenge carbon monoxide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆